This database contains information on EU funded dementia research projects, undertaken since 2007. It is the product of a mapping exercise of European funding programmes for dementia research conducted by Alzheimer Europe in 2020. This database is not an exhaustive resource of information. It contains information about European projects that are funded by European programmes including FP7, H2020, IMI, JNPD, AAL and EU Health.

Filters

(Clear all)

3-O-sulfated heparan sulfate translocation in altered membrane biology: A new strategy for early population screening and halting Alzheimer’s neurodegeneration

ArrestAD

ArrestAD proposes a novel and visionary thinking resulting from the demonstration of the central role of a particular heparan sulfate species at the intracellular level in neurons and in circulating cells in the molecular pathology of Alzheimer’s disease (AD). AD is a societal challenge for which there is neither prevention nor possible cure...
Funding Programme
Start Date
End Date
Total Funding
€ 3 991 096
European Countries Involved

A European DNA bank for deciphering the missing heritability of Alzheimer’s disease

EADB

Understanding the genetics of Alzheimer's disease (AD) is one of the best ways of improving our knowledge of the disease's underlying pathophysiological processes. Indeed, genetic factors account for up to 70% of the attributable risk in common forms of AD. The advent of genomic approaches has led to the characterization of 26 genetic determinants...

Funding Programme
Start Date
End Date
Total Funding
€ 3 644 713
European Countries Involved

A European multicentre double-blind placebo-controlled phase III trial of nilvadIpine in mild to moderate Alzheimer’s disease

NILVAD

Alzheimer’s disease (AD) is an ever-increasing public health concern among the aging population and is the most common form of dementia affecting more than 15 million individuals worldwide and around 5 million Europeans. The direct and indirect costs of AD and other dementias amount to more than €440,000 million each year (www.alz.org, 2010).Even...

Funding Programme
Start Date
End Date
Total Funding
€ 7 916 016

A multimodal approach to accelerate drug discovery and development in Alzheimer’s disease

MAP-AD

Alzheimer’s disease (AD) is a major societal challenge, impacting up to one third of the population over 85 years old. The European Commission and various international bodies have repeatedly fostered research initiatives to prevent the development or stem the progression of the disease. Several recent phase 3 clinical trials have failed to show...
Funding Programme
Start Date
End Date
Total Funding
€ 257 620
European Countries Involved

A smart, hybrid neural-computo device for drug discovery

NEUREKA

NEUREKA will bring a paradigm shift in drug discovery for neurological diseases, a sector that suffers multiple, repeated failures exacerbating the economical and societal burden of these incurable diseases. It will do so by addressing a crucial shortcoming: the lack of in vitro systems faithfully reproducing brain pathology that enable the...
Funding Programme
Start Date
End Date
Total Funding
€ 2 776 705
European Countries Involved

A WORLDWIDE E-INFRASTRUCTURE FOR COMPUTATIONAL NEUROSCIENTISTS (outGRID)

outGRID

FP7 neuGRID (www.neuGRID.eu) is being developed aiming to provide large sets of brain images paired with grid-based computationally intensive algorithms for studies of neurodegenerative diseases. Two infrastructures with similar aims are operational or under construction overseas. In Canada, the Montreal Neurological Institute (MNI) aims to develop...

Funding Programme
Start Date
End Date
Total Funding
€ 491 677
European Countries Involved

Aetionomy – Organising Mechanistic Knowledge about Neurodegenerative Diseases for the Improvement of Drug Development and Therapy

AETIONOMY

IMI’s Call 8 is geared to develop knowledge frameworks for ‘druggable mechanisms’ for two domains of pathophysiology. In response to this call, we propose (I) the development of a generic AETIONOMY pipeline to capture and infer over mechanistic knowledge of pathophysiology, and  (II) the focused application of this pipeline to derive clinically...

Funding Programme
Start Date
End Date
Total Funding
€ 17 546 060

Altered mRNA translation as a pathogenic mechanism across neurodegenerative diseases

TRANSNEURO

Neurodegenerative and neurodevelopmental diseases constitute a major health burden, and in spite of several decades of intensive research, the molecular mechanisms underlying these diseases are still poorly understood, and effective drug treatments are generally lacking. Alterations in protein synthesis have been implicated in several of these...
Funding Programme
Start Date
End Date
Total Funding
€ 1 830 000
European Countries Involved

ALzheimer COoperative Valuation in Europe

The JA will be contribute to public health programmes in Europe and develop Alzheimers disease (AD) and dementia prevention and care models in different European countries. The aim is to contribute to improvements in health by supporting and facilitating quality and efficiency of public health and healthcare policies and interventions. Synergy and...
Funding Programme
Start Date
End Date
Total Funding
€ 613 100

Alzheimer disease progression: Molecular studies of Abeta amyloid peptides aggregation and trafficking in neuronal cells

ADPROGRES

Amyloid fibrils are likely causative or contributing agents in diseases such as Alzheimer’s disease, type 2 diabetes, Parkinson’s disease, and transmissible spongiform encephalopathies. AD represents a major health problem and heavy economic burden in industrialized countries. AD is characterized in pathology by the presence of several kinds of...
Funding Programme
Start Date
End Date
Total Funding
€ 75 000
European Countries Involved

Alzheimer's disease and Zinc: the missing link ?

aLzINK

Alzheimer's disease (AD) is one of the most serious diseases mankind is now facing as its social and economical impacts are increasing fastly. AD is very complex and the amyloid-β (Aβ) peptide as well as metallic ions (mainly copper and zinc) have been linked to its aetiology. While the deleterious impact of Cu is widely acknowledged, intervention...

Funding Programme
Start Date
End Date
Total Funding
€ 1 499 948
European Countries Involved

Alzheimer’s disease data-driven insights on individual outcomes of importance

ADDITION

Alzheimer’s disease (AD) is the most common cause of dementia in the elderly, and a major reason for disability and death. The time course of AD varies between different people affected, and being able to tell in advance how the disease is likely to progress would have a great value for patient, their caregivers and for all of society. In the...
Funding Programme
Start Date
End Date
Total Funding
€ 1 100 000
European Countries Involved
 
Acknowledgement
Alzheimer Europe's database on research projects was developed as part of the 2020 Work Plan which received funding under an operating grant from the European Union’s Health Programme (2014–2020).